# Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation

> **NCT07687433** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Harbin Medical University** · enrollment: 43 (estimated)

## Conditions studied

- Rectal Cancer Patients

## Interventions

- **DRUG:** Long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib

## Key facts

- **NCT ID:** NCT07687433
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-05-29
- **Primary completion:** 2028-05-29
- **Final completion:** 2029-05-29
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07687433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07687433, "Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07687433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*